COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS



(In thousands)	June 30, 2015			December 31, 2014
Accounts receivable, net
Accounts receivable	$	29,045		$	21,875
Less: allowance for doubtful accounts	(2,065		)	(1,906		)
	$	26,980		$	19,969
Inventories, net
Finished products	$	13,830		$	12,116
Work in-process	1,619			1,011
Raw materials	5,782			4,116
Less: inventory reserve	(712		)	(639		)
	$	20,519		$	16,604
Prepaid expenses and other current assets
Prepaid supplies	$	1,441		$	1,123
Prepaid insurance	613			968
Other receivables	1,107			669
Taxes recoverable	3,074			2,417
Other	3,388			4,212
	$	9,623		$	9,389
Intangible assets, net:
Technologies	$	52,287		$	52,508
Customer relationships	55,750			22,108
Product registrations	8,088			8,763
Trade names	3,411			3,483
Covenants not to compete	8,620			8,639
Other	4,889			1,079
Less: accumulated amortization	(38,798		)	(33,931		)
	$	94,247		$	62,649
Accrued expenses:
Taxes payable	$	2,592		$	77
Deferred revenue	75,159			4,185
Clinical trials	8,534			8,643
Professional fees	1,724			1,860
Employee benefits	5,456			4,127
Contingent consideration	41,146			27,352
Other	15,232			14,668
	$	149,843		$	60,912



(In thousands)	June 30, 2015		December 31, 2014
Other long-term liabilities:
Contingent consideration – OPKO Renal	$	19,183	$	36,529
Contingent consideration – OPKO Health Europe	225		254
Contingent consideration – OPKO Diagnostics	13,342		6,992
Contingent consideration – CURNA	433		440
Mortgages and other debts payable	2,148		2,434
Deferred tax liabilities	172,458		167,153
Deferred revenue	197,279		2,526
Other	3,753		1,030
	$	408,821	$	217,358

All of the intangible assets and goodwill acquired relate to our acquisitions of OPKO Chile, including the intangible assets and goodwill related to the ALS acquisition, OPKO Mexico, CURNA, OPKO Diagnostics, FineTech, OPKO Health Europe, OPKO Lab, OPKO Brazil, OPKO Renal, OPKO Biologics, OPKO Uruguay Ltda., EirGen and SciVac, a consolidated VIE. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in the U.S., Chile, Canada, Mexico, Spain, Ireland, or Israel.

At June 30, 2015, the changes in value of the intangible assets and goodwill are primarily due to the acquisition of EirGen and foreign currency fluctuations between the Chilean and Mexican pesos, the Euro and the Shekel against the U.S. dollar.

The following table reflects the changes in Goodwill during the six months ended June 30, 2015.



	2015
(In thousands)	Balance at January 1st		Acquisitions		Foreign exchange			Balance at June 30th
Pharmaceuticals
CURNA	$	4,827	$	—	$	—		$	4,827
OPKO Mexico	100		—		(5		)	95
OPKO Chile	5,283		—		(243		)	5,040
OPKO Health Europe	8,013		—		(699		)	7,314
FineTech	11,698		—		—			11,698
SciVac	1,553		—		49			1,602
OPKO Renal	2,069		—		—			2,069
OPKO Biologics	139,784		—		—			139,784
EirGen Pharma Ltd	—		66,823		(610		)	66,213
Diagnostics
OPKO Diagnostics	17,977		—		—			17,977
OPKO Lab	32,988		—		—			32,988
	$	224,292	$	66,823	$	(1,508	)	$	289,607